Datasets:

Modalities:
Tabular
Text
Formats:
csv
Languages:
English
DOI:
Libraries:
Datasets
pandas
License:
Dataset Viewer
Auto-converted to Parquet
targetId
stringlengths
15
15
diseaseId
stringlengths
9
15
nctid
stringlengths
11
11
clinicalStatus
stringclasses
9 values
clinicalPhase
int64
0
4
studyStartDate
stringdate
1965-04-01 00:00:00
2050-12-01 00:00:00
stopStatus
stringclasses
3 values
isStopped
stringclasses
1 value
phase4
stringclasses
1 value
phase3
stringclasses
1 value
phase2
stringclasses
1 value
id
int64
0
1,709B
why_stopped
stringlengths
2
254
phase
stringclasses
7 values
start_date
stringlengths
10
10
status
stringclasses
3 values
last_update_posted_date
stringlengths
10
10
completion_date
stringlengths
10
10
prediction
stringclasses
15 values
metaprediction
stringclasses
6 values
max_l2g
float64
0.05
0.9
l2g_075
stringclasses
1 value
l2g_05
stringclasses
1 value
l2g_025
stringclasses
1 value
l2g_01
stringclasses
1 value
l2g_005
stringclasses
1 value
taId
stringclasses
23 values
taLabel
stringclasses
24 values
taLabelSimple
stringclasses
2 values
gc
float64
0
5
lof_tolerance
stringclasses
2 values
rnaDistribution
stringclasses
5 values
rnaSpecificity
stringclasses
5 values
partnersBin
stringclasses
4 values
datasourceId
stringclasses
22 values
datatypeId
stringclasses
7 values
total
int64
413k
413k
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004779
EFO_1001249
NCT00699036
Unknown status
2
2007-04-01
null
null
null
null
Phase II+
120,259,084,622
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
2
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT00699036
Unknown status
2
2007-04-01
null
null
null
null
Phase II+
120,259,084,622
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT00699036
Unknown status
2
2007-04-01
null
null
null
null
Phase II+
120,259,084,622
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT04972396
Recruiting
1
2021-10-05
null
null
null
null
null
343,597,383,747
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
2
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT04972396
Recruiting
1
2021-10-05
null
null
null
null
null
343,597,383,747
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT04972396
Recruiting
1
2021-10-05
null
null
null
null
null
343,597,383,747
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT02406066
Completed
1
2015-03-01
null
null
null
null
null
824,633,722,293
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT02406066
Completed
1
2015-03-01
null
null
null
null
null
824,633,722,293
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT02406066
Completed
1
2015-03-01
null
null
null
null
null
824,633,722,293
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00802412
Completed
2
2009-01-01
null
null
null
null
Phase II+
893,353,198,669
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00802412
Completed
2
2009-01-01
null
null
null
null
Phase II+
893,353,198,669
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00802412
Completed
2
2009-01-01
null
null
null
null
Phase II+
893,353,198,669
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00208858
Completed
2
2004-12-01
null
null
null
null
Phase II+
1,185,410,975,178
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00208858
Completed
2
2004-12-01
null
null
null
null
Phase II+
1,185,410,975,178
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00208858
Completed
2
2004-12-01
null
null
null
null
Phase II+
1,185,410,975,178
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT03813121
Completed
1
2019-06-01
null
null
null
null
null
1,365,799,601,280
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT03813121
Completed
1
2019-06-01
null
null
null
null
null
1,365,799,601,280
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT03813121
Completed
1
2019-06-01
null
null
null
null
null
1,365,799,601,280
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT01182766
Active, not recruiting
2
2011-09-01
null
null
null
null
Phase II+
1,374,389,536,597
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT01182766
Active, not recruiting
2
2011-09-01
null
null
null
null
Phase II+
1,374,389,536,597
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT01182766
Active, not recruiting
2
2011-09-01
null
null
null
null
Phase II+
1,374,389,536,597
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00755716
Completed
3
2006-04-01
null
null
null
Phase III+
Phase II+
1,382,979,470,922
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00755716
Completed
3
2006-04-01
null
null
null
Phase III+
Phase II+
1,382,979,470,922
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00755716
Completed
3
2006-04-01
null
null
null
Phase III+
Phase II+
1,382,979,470,922
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
null
null
4
null
null
null
Phase IV
Phase III+
Phase II+
1,597,727,834,458
null
null
null
null
null
null
null
null
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
1
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
null
null
4
null
null
null
Phase IV
Phase III+
Phase II+
1,597,727,834,458
null
null
null
null
null
null
null
null
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
null
null
4
null
null
null
Phase IV
Phase III+
Phase II+
1,597,727,834,458
null
null
null
null
null
null
null
null
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
NCT00637780
Terminated
4
2010-06-01
Terminated
stopped
Phase IV
Phase III+
Phase II+
618,475,292,173
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
Phase 4
30/06/2010
Terminated
23/02/2017
31/01/2014
Business_Administrative
Business_Administrative
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
1
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
NCT00637780
Terminated
4
2010-06-01
Terminated
stopped
Phase IV
Phase III+
Phase II+
618,475,292,173
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
Phase 4
30/06/2010
Terminated
23/02/2017
31/01/2014
Business_Administrative
Business_Administrative
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
NCT00637780
Terminated
4
2010-06-01
Terminated
stopped
Phase IV
Phase III+
Phase II+
618,475,292,173
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
Phase 4
30/06/2010
Terminated
23/02/2017
31/01/2014
Business_Administrative
Business_Administrative
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000014138
EFO_1002001
NCT01238211
Active, not recruiting
2
2010-12-14
null
null
null
null
Phase II+
523,986,011,570
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
EFO_1002001
NCT01238211
Active, not recruiting
2
2010-12-14
null
null
null
null
Phase II+
523,986,011,570
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
EFO_1002001
NCT01238211
Active, not recruiting
2
2010-12-14
null
null
null
null
Phase II+
523,986,011,570
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00003204
Completed
3
1998-03-01
null
null
null
Phase III+
Phase II+
292,057,776,621
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00003204
Completed
3
1998-03-01
null
null
null
Phase III+
Phase II+
292,057,776,621
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00003204
Completed
3
1998-03-01
null
null
null
Phase III+
Phase II+
292,057,776,621
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00510887
Terminated
2
2007-01-01
Terminated
stopped
null
null
Phase II+
352,187,319,161
Low accrual.
Phase 2
31/01/2007
Terminated
12/05/2014
30/09/2013
Insufficient_Enrollment
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00510887
Terminated
2
2007-01-01
Terminated
stopped
null
null
Phase II+
352,187,319,161
Low accrual.
Phase 2
31/01/2007
Terminated
12/05/2014
30/09/2013
Insufficient_Enrollment
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00510887
Terminated
2
2007-01-01
Terminated
stopped
null
null
Phase II+
352,187,319,161
Low accrual.
Phase 2
31/01/2007
Terminated
12/05/2014
30/09/2013
Insufficient_Enrollment
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02348216
Active, not recruiting
1
2015-04-21
null
null
null
null
null
377,957,122,485
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02348216
Active, not recruiting
1
2015-04-21
null
null
null
null
null
377,957,122,485
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02348216
Active, not recruiting
1
2015-04-21
null
null
null
null
null
377,957,122,485
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00169208
Completed
2
2001-04-01
null
null
null
null
Phase II+
609,885,357,182
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00169208
Completed
2
2001-04-01
null
null
null
null
Phase II+
609,885,357,182
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00169208
Completed
2
2001-04-01
null
null
null
null
Phase II+
609,885,357,182
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00924326
Completed
1
2009-02-17
null
null
null
null
null
755,914,245,467
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00924326
Completed
1
2009-02-17
null
null
null
null
null
755,914,245,467
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00924326
Completed
1
2009-02-17
null
null
null
null
null
755,914,245,467
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01321541
Completed
3
2011-04-20
null
null
null
Phase III+
Phase II+
876,173,329,055
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01321541
Completed
3
2011-04-20
null
null
null
Phase III+
Phase II+
876,173,329,055
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01321541
Completed
3
2011-04-20
null
null
null
Phase III+
Phase II+
876,173,329,055
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02295722
Unknown status
1
2015-04-01
null
null
null
null
null
42,949,674,404
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02295722
Unknown status
1
2015-04-01
null
null
null
null
null
42,949,674,404
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02295722
Unknown status
1
2015-04-01
null
null
null
null
null
42,949,674,404
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00110071
Completed
1
2005-01-01
null
null
null
null
null
77,309,411,723
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00110071
Completed
1
2005-01-01
null
null
null
null
null
77,309,411,723
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00110071
Completed
1
2005-01-01
null
null
null
null
null
77,309,411,723
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00119392
Completed
2
2004-06-01
null
null
null
null
Phase II+
240,518,169,289
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00119392
Completed
2
2004-06-01
null
null
null
null
Phase II+
240,518,169,289
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00119392
Completed
2
2004-06-01
null
null
null
null
Phase II+
240,518,169,289
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01529827
Completed
2
2012-02-28
null
null
null
null
Phase II+
317,827,580,785
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01529827
Completed
2
2012-02-28
null
null
null
null
Phase II+
317,827,580,785
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01529827
Completed
2
2012-02-28
null
null
null
null
Phase II+
317,827,580,785
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00562965
Terminated
3
2007-11-01
Terminated
stopped
null
Phase III+
Phase II+
369,367,188,591
See termination reason in detailed description.
Phase 3
30/11/2007
Terminated
09/01/2018
30/04/2011
No_Context
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00562965
Terminated
3
2007-11-01
Terminated
stopped
null
Phase III+
Phase II+
369,367,188,591
See termination reason in detailed description.
Phase 3
30/11/2007
Terminated
09/01/2018
30/04/2011
No_Context
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00562965
Terminated
3
2007-11-01
Terminated
stopped
null
Phase III+
Phase II+
369,367,188,591
See termination reason in detailed description.
Phase 3
30/11/2007
Terminated
09/01/2018
30/04/2011
No_Context
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00079443
Terminated
2
2004-01-01
Terminated
stopped
null
null
Phase II+
412,316,861,764
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00079443
Terminated
2
2004-01-01
Terminated
stopped
null
null
Phase II+
412,316,861,764
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00079443
Terminated
2
2004-01-01
Terminated
stopped
null
null
Phase II+
412,316,861,764
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01303887
Unknown status
3
2009-10-01
null
null
null
Phase III+
Phase II+
601,295,421,934
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01303887
Unknown status
3
2009-10-01
null
null
null
Phase III+
Phase II+
601,295,421,934
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01303887
Unknown status
3
2009-10-01
null
null
null
Phase III+
Phase II+
601,295,421,934
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00393107
Completed
2
2000-03-01
null
null
null
null
Phase II+
953,482,741,355
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00393107
Completed
2
2000-03-01
null
null
null
null
Phase II+
953,482,741,355
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00393107
Completed
2
2000-03-01
null
null
null
null
Phase II+
953,482,741,355
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03019640
Completed
2
2017-10-10
null
null
null
null
Phase II+
970,662,610,863
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03019640
Completed
2
2017-10-10
null
null
null
null
Phase II+
970,662,610,863
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03019640
Completed
2
2017-10-10
null
null
null
null
Phase II+
970,662,610,863
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00140569
Completed
3
1994-01-01
null
null
null
Phase III+
Phase II+
1,099,511,629,558
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00140569
Completed
3
1994-01-01
null
null
null
Phase III+
Phase II+
1,099,511,629,558
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00140569
Completed
3
1994-01-01
null
null
null
Phase III+
Phase II+
1,099,511,629,558
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03128359
Active, not recruiting
2
2017-05-30
null
null
null
null
Phase II+
1,357,209,666,455
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03128359
Active, not recruiting
2
2017-05-30
null
null
null
null
Phase II+
1,357,209,666,455
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03128359
Active, not recruiting
2
2017-05-30
null
null
null
null
Phase II+
1,357,209,666,455
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00850499
Terminated
2
2009-09-01
Terminated
stopped
null
null
Phase II+
1,425,929,143,471
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00850499
Terminated
2
2009-09-01
Terminated
stopped
null
null
Phase II+
1,425,929,143,471
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00850499
Terminated
2
2009-09-01
Terminated
stopped
null
null
Phase II+
1,425,929,143,471
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03105336
Active, not recruiting
2
2017-06-20
null
null
null
null
Phase II+
1,606,317,770,278
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
End of preview. Expand in Data Studio

OpenTargets Clinical Evidence Dataset

This OpenTargets clinical evidence dataset represents a comprehensive collection of clinical trial data linking genetic targets to diseases, containing 32 structured columns that capture the complete lifecycle of clinical studies. The dataset is annotated with clinical trials' predicted stop reason and genetic evidence when available and was referenced in the Why Clinical Trials Stop: The Role of Genetics. The study analyzed 28,842 stopped clinical trials and demonstrated that genetic evidence significantly influences trial efficacy.

This dataset was generated with the 22.04 Open Targets Data with this script.

Tutorial

To access the dataset, you can use HF datasets:

from datasets import load_dataset

ds = load_dataset("opentargets/clinical_evidence")

# see first record
next(ds.iter(1))

Features

The dataset contains a lot of genetic and clinical features which can be used for ML modelling.

The features are summarized in the table below:

Column Name Data Type Description Example Values
targetId string Ensembl gene identifier representing the target gene ENSG00000004468, ENSG00000065518
diseaseId string Disease ontology identifier using EFO or MONDO terms EFO_0000203, MONDO_0005148
nctid string ClinicalTrials.gov identifier for the clinical trial NCT03236428, NCT01089192
clinicalStatus string Current status of the clinical trial Active, not recruiting, Completed, Withdrawn, Terminated, Suspended
clinicalPhase int64 Numeric representation of the clinical trial phase 1, 2, 3, 4
studyStartDate string Date when the clinical trial began (YYYY-MM-DD format) 2017-11-24, 2016-11-30
stopStatus string Reason for trial discontinuation (null if ongoing/completed normally) null, Withdrawn, Terminated, Suspended
isStopped string Boolean indicator if the trial was stopped stopped, null
phase4 string Indicates if this is a Phase IV (post-marketing) trial Phase IV, null
phase3 string Indicates if this is a Phase III trial Phase III+, null
phase2 string Indicates if this is a Phase II trial Various phase indicators, null
id int64 Internal record identifier Numeric identifiers
why_stopped string Detailed reason why a trial was discontinued Trial-specific discontinuation reasons
phase string String representation of the trial phase Phase descriptors
status string Trial status information Status descriptions
last_update_posted_date string Most recent update to the trial record Date strings
completion_date string Date when the trial was completed (if applicable) Date strings
prediction string Computational prediction about the target-disease association Prediction values
metaprediction string Meta-analysis prediction combining multiple evidence sources Meta-prediction values
max_l2g double Maximum locus-to-gene (L2G) score indicating genetic evidence strength Floating point scores
l2g_075 string L2G score threshold at 0.75 confidence level Threshold indicators
l2g_05 string L2G score threshold at 0.5 confidence level Threshold indicators
l2g_025 string L2G score threshold at 0.25 confidence level Threshold indicators
l2g_01 string L2G score threshold at 0.1 confidence level Threshold indicators
l2g_005 string L2G score threshold at 0.05 confidence level Threshold indicators
taId string Therapeutic area identifier Therapeutic area codes
taLabel string Full therapeutic area label Therapeutic area names
taLabelSimple string Simplified therapeutic area label Simplified area names
gc double Gene constraint score Floating point constraint scores
lof_tolerance string Loss-of-function tolerance classification Tolerance classifications
rnaDistribution string RNA expression distribution pattern Distribution patterns
rnaSpecificity string RNA expression specificity Specificity measures
partnersBin string Protein interaction partners classification Partner classifications
datasourceId string Identifier for the data source Data source identifiers
datatypeId string Type of evidence data Evidence type identifiers
total int64 Total count or score for the evidence Numeric totals

Citation

@article{razuvayevskaya2023clinical,
  title={Why Clinical Trials Stop: The Role of Genetics},
  author={Razuvayevskaya, Olesya and Lopez, Irene and Dunham, Ian and Ochoa, David},
  journal={medRxiv},
  pages={2023--02},
  year={2023},
  publisher={Cold Spring Harbor Laboratory},
  doi={10.1101/2023.02.07.23285407}
}

OpenTargets

Interested in other datasets or research related to drug or target discovery? Visit OpenTargets Platform

Reproduction

Dataset was generated with the 22.04 Open Targets Data with this script.

Downloads last month
48